ArticleMolecular medicine reports2017
Farnesoid X receptor deletion improves cardiac function, structure and remodeling following myocardial infarction in mice.
Article in Molecular medicine reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 27 citations in OpenAlex.
- Proteomic Analysis of Effects of Spironolactone in Heart Failure With Preserved Ejection Fraction.Circulation. Heart failure · 2022Trial
- Discovery of sulfonyl benzoic acid derivatives with joint TGR5-agonist and FXR-antagonist activity for myocardial ischemia/reperfusion injury protection.Acta pharmaceutica Sinica. B · 2026Article
- Microbiome-Associated Drug Response Variability in Heart Failure Treatment.Life (Basel, Switzerland) · 2026Review
- Role of Bile Acid Receptors in the Development and Function of Diabetic Nephropathy.Kidney international reports · 2024Review
- Bile Acids and Bilirubin Role in Oxidative Stress and Inflammation in Cardiovascular Diseases.Diseases (Basel, Switzerland) · 2024Review
- Atherosclerosis, gut microbiome, and exercise in a meta-omics perspective: a literature review.PeerJ · 2024Review
- Gut microbiota and bile acids: Metabolic interactions and impacts on diabetic kidney disease.Current research in microbial sciences · 2024Review
- The Role of Bile Acids in Cardiovascular Diseases: from Mechanisms to Clinical Implications.Aging and disease · 2023Article
- The role of the gut microbiota in health and cardiovascular diseases.Molecular biomedicine · 2022Review
- Biliary cirrhosis-induced cardiac abnormality in rats: Interaction between Farnesoid-X-activated receptors and the cardiac uncoupling proteins 2 and 3.Iranian journal of basic medical sciences · 2022Article
- Knowledge Mapping of the Links Between the Gut Microbiota and Heart Failure: A Scientometric Investigation (2006-2021).Frontiers in cardiovascular medicine · 2022Article
- Gut Microbiome and Precision Nutrition in Heart Failure: Hype or Hope?Current heart failure reports · 2021Review
- The Correlation Between Heart Failure and Gut Microbiome Metabolites.Infectious microbes & diseases · 2020Review
- Gastrointestinal Mechanisms Underlying the Cardiovascular Effect of Metformin.Pharmaceuticals (Basel, Switzerland) · 2020Review
- Farnesoid X receptor knockout protects brain against ischemic injury through reducing neuronal apoptosis in mice.Journal of neuroinflammation · 2020Article
- The gut microbiome and heart failure: A better gut for a better heart.Reviews in endocrine & metabolic disorders · 2019Review
- Ivabradine promotes angiogenesis and reduces cardiac hypertrophy in mice with myocardial infarction.Anatolian journal of cardiology · 2018Article
- DOT1L Epigenetically Regulates Autophagy and Mitochondria Fusion in Cell Lines of Renal Cancer.Technology in cancer research & treatmentArticle
- Diagnosis and Management of Cirrhotic Cardiomyopathy.Journal of clinical and experimental hepatologyArticle
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The farnesoid X receptor (FXR) is implicated in cholesterol and bile acid homeostasis; however, its role following myocardial infarction (MI) has yet to be elucidated. The aim of the present study was to investigate the effects of FXR knockout on left ventricular (LV) remodeling following MI. Coronary arteries of wild type (WT) and FXR‑/‑ mice were permanently occluded to cause MI, and serial echocardiographic and histological tests were conducted. At 4 weeks post‑MI, FXR‑/‑ mice exhibited significantly smaller infarct sizes (34.20±2.58 vs. 44.20±3.19%), improved ejection fraction (47.31±1.08 vs. 37.64±0.75%) and reduced LV chamber dilation compared with WT mice. LV remodeling was significant as early as 7 days post‑MI in FXR‑/‑ compared with WT mice. Histological features associated with enhanced long‑term remodeling and improved functionality, such as increased angiogenesis via detection of CD31 and reduced fibrosis, were observed in the FXR‑/‑ group. Myocyte apoptosis within the infarcted zones appeared significantly reduced by day 7 in FXR‑/‑ mice. In conclusion, the results of the present study suggested that FXR knockout may participate in the preservation of post‑MI cardiac functionality, via reducing fibrosis and chronic apoptosis, and ameliorating ventricular function.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.